CSPC Pharmaceutical Group saw its shares surge 5.43% after announcing an exclusive licensing agreement with AstraZeneca for a promising lipid-lowering therapy. The deal grants CSPC the rights to AstraZeneca's YS2302018 asset, with the Chinese pharmaceutical company receiving an upfront payment of $100 million.
Under the terms of the agreement, CSPC is also eligible to receive up to $370 million in potential development milestone payments and a staggering $1.55 billion in potential sales milestone payments. This significant deal highlights AstraZeneca's commitment to partnering with innovative companies and leveraging their expertise in specific therapeutic areas.
The licensing agreement is expected to provide CSPC with a valuable addition to its pipeline and strengthen its position in the rapidly growing cardiovascular market. For AstraZeneca, the deal allows the company to focus on its core therapeutic areas while capitalizing on CSPC's capabilities in developing and commercializing the asset in China and other potential markets.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。